-
公开(公告)号:US09678084B2
公开(公告)日:2017-06-13
申请号:US13488293
申请日:2012-06-04
申请人: Michael Pichichero , Kyle Liu
发明人: Michael Pichichero , Kyle Liu
IPC分类号: G01N33/68
CPC分类号: G01N33/6893 , G01N2333/52 , G01N2333/5428 , G01N2333/70525 , G01N2800/14 , G01N2800/26
摘要: Compositions and methods related to diagnosis of ear infections and acute otitis media.
-
公开(公告)号:US09632096B2
公开(公告)日:2017-04-25
申请号:US14530584
申请日:2014-10-31
发明人: Mirko Corselli
IPC分类号: G01N15/14 , G01N33/68 , G01N33/50 , G01N33/569 , G01N15/10
CPC分类号: G01N33/6872 , G01N15/14 , G01N15/1459 , G01N33/5091 , G01N33/56966 , G01N33/6869 , G01N2015/1006 , G01N2015/1402 , G01N2015/149 , G01N2333/5412 , G01N2333/70525
摘要: Methods of assessing the immunomodulatory potential of a multipotent stromal cell (MSC) population are provided. Aspects of the methods include evaluating the amount of CD54/IL-6 associated with an MSC in a sample of the MSC population to obtain a CD54/IL-6 result and providing an assessment of the immunomodulatory potential of the MSC population based on the obtained CD54/IL-6 result. Also provided are systems and kits that find use in practicing the subject methods.
-
公开(公告)号:US20170023590A1
公开(公告)日:2017-01-26
申请号:US15287162
申请日:2016-10-06
CPC分类号: G01N33/6893 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/626 , C07K2317/76 , G01N33/6863 , G01N2333/4716 , G01N2333/485 , G01N2333/522 , G01N2333/5412 , G01N2333/5421 , G01N2333/5434 , G01N2333/545 , G01N2333/57 , G01N2333/70503 , G01N2333/70525 , G01N2333/70539 , G01N2333/7151 , G01N2333/7452 , G01N2333/75 , G01N2333/775 , G01N2333/8139 , G01N2333/8146 , G01N2333/974 , G01N2800/226 , G01N2800/347 , G01N2800/50 , G01N2800/52
摘要: The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.
摘要翻译: 本公开提供了生物标志物蛋白质,其浓度或活性水平的变化与非典型溶血性尿毒症综合征(aHUS)相关,或临床意义上用补体抑制剂治疗HUS。 还提供了用于询问生物流体中一种或多种生物标记蛋白的浓度和/或活性的组合物和方法。 组合物和方法可用于评估发展为高血压的风险,诊断高血压,确定受试者是否正在经历第一次急性呈现的HUS,监测进展或减轻HUS,和/或监测对治疗的反应 补体抑制剂或优化这种治疗。
-
公开(公告)号:US20160154009A1
公开(公告)日:2016-06-02
申请号:US15013833
申请日:2016-02-02
CPC分类号: G01N33/6893 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/626 , C07K2317/76 , G01N33/6863 , G01N2333/4716 , G01N2333/485 , G01N2333/522 , G01N2333/5412 , G01N2333/5421 , G01N2333/5434 , G01N2333/545 , G01N2333/57 , G01N2333/70503 , G01N2333/70525 , G01N2333/70539 , G01N2333/7151 , G01N2333/7452 , G01N2333/75 , G01N2333/775 , G01N2333/8139 , G01N2333/8146 , G01N2333/974 , G01N2800/226 , G01N2800/347 , G01N2800/50 , G01N2800/52
摘要: The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.
摘要翻译: 本公开提供了生物标志物蛋白质,其浓度或活性水平的变化与非典型溶血性尿毒症综合征(aHUS)相关,或临床意义上用补体抑制剂治疗HUS。 还提供了用于询问生物流体中一种或多种生物标记蛋白的浓度和/或活性的组合物和方法。 组合物和方法可用于评估发展为高血压的风险,诊断高血压,确定受试者是否正在经历第一次急性呈现的HUS,监测进展或减轻HUS,和/或监测对治疗的反应 补体抑制剂或优化这种治疗。
-
公开(公告)号:US20160139153A1
公开(公告)日:2016-05-19
申请号:US14943101
申请日:2015-11-17
IPC分类号: G01N33/68
CPC分类号: G01N33/6896 , A61K38/1709 , G01N33/543 , G01N2333/521 , G01N2333/705 , G01N2333/70503 , G01N2333/70525 , G01N2800/2857
摘要: The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject. Also provided are methods for detecting seizure, methods for predicting seizure, use of sICAM-5 in the treatment of seizure, methods for assessing the effectiveness of a treatment of seizure, and diagnostic kits.
-
公开(公告)号:US09291614B2
公开(公告)日:2016-03-22
申请号:US14202721
申请日:2014-03-10
CPC分类号: G01N33/5029 , B01L3/5027 , G01N33/5005 , G01N33/5011 , G01N33/5061 , G01N33/5088 , G01N33/86 , G01N2333/4703 , G01N2333/70525
摘要: A method of assaying wound healing can include: growing cells on the matrix in the first flow channel; introducing an agent that removes the matrix from the junction; introducing a matrix material into the second flow channel so as to form the second matrix in the second flow channel and junction; and detecting cellular migration into the junction onto the second matrix. The agent that removes the matrix can include a biomolecule or chemical agent. The method can include removing cells in the matrix in the junction before introducing the matrix material into the second flow channel. A bioactive agent can be introduced into the junction to determine if it modulates cellular migration and/or clot formation into the intersection openings of tissue and vascular channels.
摘要翻译: 测定伤口愈合的方法可以包括:在第一流动通道中在基质上生长细胞; 引入从接合处去除基质的试剂; 将基质材料引入到第二流动通道中,以便在第二流动通道和结中形成第二基质; 并检测细胞迁移到第二基质上的结。 去除基质的试剂可以包括生物分子或化学试剂。 该方法可以包括在将基质材料引入第二流动通道之前去除接合中的基体中的细胞。 可以将生物活性剂引入接头以确定其是否调节细胞迁移和/或凝块形成到组织和血管通道的交叉开口中。
-
公开(公告)号:US09289426B2
公开(公告)日:2016-03-22
申请号:US12076759
申请日:2008-03-21
IPC分类号: A61K31/506 , A61K31/7105 , G01N33/574
CPC分类号: C07K16/2869 , A61K31/506 , A61K31/7105 , A61K38/06 , C07K2317/76 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2320/30 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/57484 , G01N33/57492 , G01N2333/70525 , G01N2333/726
摘要: The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of ETRB, ET-1, ICAM-1, or another protein found herein to play a role in homing of T cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of T cells to a solid tumor, or a nucleotide molecule encoding same.
-
公开(公告)号:US20150216857A1
公开(公告)日:2015-08-06
申请号:US14609795
申请日:2015-01-30
发明人: Thomas Gadek , John Burnier
IPC分类号: A61K31/4725
CPC分类号: A61K31/4725 , A61B3/101 , A61B3/145 , A61K9/0014 , A61K9/0019 , A61K9/0043 , A61K9/0048 , A61K9/0051 , A61K9/0053 , A61K31/197 , A61K31/198 , A61K31/275 , A61K31/341 , A61K31/352 , A61K31/381 , A61K31/40 , A61K31/404 , A61K31/405 , A61K31/4162 , A61K31/4184 , A61K31/4192 , A61K31/44 , A61K31/4709 , A61K31/472 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/517 , A61K31/5377 , A61K31/54 , A61K31/541 , A61K33/00 , A61K33/06 , A61K38/07 , A61K38/08 , A61K38/12 , A61K38/1703 , A61K45/06 , C07C279/28 , C07C317/50 , C07D207/06 , C07D217/00 , C07D217/02 , C07D217/06 , C07D217/20 , C07D217/26 , C07D307/52 , C07D333/38 , C07D401/06 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , G01N33/5011 , G01N33/5032 , G01N33/5047 , G01N33/566 , G01N33/6872 , G01N2333/705 , G01N2333/70525 , G01N2333/70546 , G01N2500/02 , G01N2500/04 , G01N2500/10 , G01N2500/20 , G01N2800/16 , Y10S514/912 , Y10S514/914
摘要: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
-
公开(公告)号:US20150182520A1
公开(公告)日:2015-07-02
申请号:US14609967
申请日:2015-01-30
发明人: Thomas Gadek , John Burnier
IPC分类号: A61K31/4725
CPC分类号: A61K31/4725 , A61B3/101 , A61B3/145 , A61K9/0014 , A61K9/0019 , A61K9/0043 , A61K9/0048 , A61K9/0051 , A61K9/0053 , A61K31/197 , A61K31/198 , A61K31/275 , A61K31/341 , A61K31/352 , A61K31/381 , A61K31/40 , A61K31/404 , A61K31/405 , A61K31/4162 , A61K31/4184 , A61K31/4192 , A61K31/44 , A61K31/4709 , A61K31/472 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/517 , A61K31/5377 , A61K31/54 , A61K31/541 , A61K33/00 , A61K33/06 , A61K38/07 , A61K38/08 , A61K38/12 , A61K38/1703 , A61K45/06 , C07C279/28 , C07C317/50 , C07D207/06 , C07D217/00 , C07D217/02 , C07D217/06 , C07D217/20 , C07D217/26 , C07D307/52 , C07D333/38 , C07D401/06 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , G01N33/5011 , G01N33/5032 , G01N33/5047 , G01N33/566 , G01N33/6872 , G01N2333/705 , G01N2333/70525 , G01N2333/70546 , G01N2500/02 , G01N2500/04 , G01N2500/10 , G01N2500/20 , G01N2800/16 , Y10S514/912 , Y10S514/914
摘要: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
-
公开(公告)号:US20150175577A1
公开(公告)日:2015-06-25
申请号:US14610318
申请日:2015-01-30
发明人: Thomas Gadek , John Burnier
IPC分类号: C07D405/06
CPC分类号: A61K31/4725 , A61B3/101 , A61B3/145 , A61K9/0014 , A61K9/0019 , A61K9/0043 , A61K9/0048 , A61K9/0051 , A61K9/0053 , A61K31/197 , A61K31/198 , A61K31/275 , A61K31/341 , A61K31/352 , A61K31/381 , A61K31/40 , A61K31/404 , A61K31/405 , A61K31/4162 , A61K31/4184 , A61K31/4192 , A61K31/44 , A61K31/4709 , A61K31/472 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/517 , A61K31/5377 , A61K31/54 , A61K31/541 , A61K33/00 , A61K33/06 , A61K38/07 , A61K38/08 , A61K38/12 , A61K38/1703 , A61K45/06 , C07C279/28 , C07C317/50 , C07D207/06 , C07D217/00 , C07D217/02 , C07D217/06 , C07D217/20 , C07D217/26 , C07D307/52 , C07D333/38 , C07D401/06 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , G01N33/5011 , G01N33/5032 , G01N33/5047 , G01N33/566 , G01N33/6872 , G01N2333/705 , G01N2333/70525 , G01N2333/70546 , G01N2500/02 , G01N2500/04 , G01N2500/10 , G01N2500/20 , G01N2800/16 , Y10S514/912 , Y10S514/914
摘要: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
-
-
-
-
-
-
-
-
-